Skip to main content


Fig. 2 | Respiratory Research

Fig. 2

From: Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

Fig. 2

TDI focal score at Week 24 (a) and over 24 weeks (b). Data are LS means ± SE for the pooled ITT population; *** p < 0.001 vs placebo, p < 0.05 vs aclidinium †† p < 0.01 vs formoterol; FDC, aclidinium/formoterol fixed-dose combination; ITT, intent-to-treat; LS, least squares; MCID, minimum clinically important difference; ns, not significant; SE, standard error; TDI, Transitional Dyspnoea Index

Back to article page